Share Price and Basic Stock Data
Last Updated: January 21, 2026, 6:06 pm
| PEG Ratio | -36.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Neogen Chemicals Ltd operates in the specialty chemicals sector, focusing on advanced chemical solutions. The company’s market capitalization stood at ₹3,470 Cr, with its stock priced at ₹1,316. Neogen reported sales of ₹686 Cr for the fiscal year ending March 2023, showing an increase from ₹575 Cr in the previous year. The company has demonstrated consistent revenue growth, with a year-on-year increase in sales from ₹487 Cr in March 2022 to ₹701 Cr in March 2024. Quarterly sales figures indicate fluctuations, with a peak of ₹203.92 Cr in March 2023 and a decline to ₹168.24 Cr in September 2023, reflecting seasonal variations in demand. The trailing twelve months (TTM) revenue reached ₹795 Cr, suggesting a strong recovery trajectory post-pandemic. Neogen’s operational performance is underpinned by its focus on high-margin specialty products, which have contributed to its competitive positioning within the industry.
Profitability and Efficiency Metrics
Neogen Chemicals reported an operating profit margin (OPM) of 16.91%, indicative of its ability to manage costs effectively while maintaining pricing power in a competitive market. The company’s return on equity (ROE) was recorded at 7.36%, while return on capital employed (ROCE) stood at 10.7%, reflecting moderate efficiency in generating profits from shareholders’ equity and overall capital. Net profit for the fiscal year 2023 was ₹50 Cr, slightly down from ₹45 Cr in the previous year. The company’s interest coverage ratio (ICR) of 2.89x demonstrates adequate capacity to meet interest obligations, although it remains below the industry norm, which typically ranges higher. The profit before tax (PBT) margin has fluctuated, reflecting operational challenges, culminating in a PBT of ₹66 Cr for March 2025. Overall, while Neogen exhibits solid profitability metrics, the declining trends in net profit and PBT margins highlight areas requiring strategic focus.
Balance Sheet Strength and Financial Ratios
Neogen Chemicals’ balance sheet reflects a robust financial structure with total assets amounting to ₹1,949 Cr as of September 2025. The company’s equity capital stood at ₹26 Cr, supported by reserves of ₹803 Cr, indicating a strong buffer for future growth initiatives. However, total borrowings reached ₹776 Cr, which translates to a debt-to-equity ratio of 0.71x, suggesting a moderate level of leverage. The current ratio was reported at 1.36x, indicating adequate liquidity to cover short-term liabilities, while the quick ratio of 0.94x suggests potential challenges in immediate cash availability. The company’s book value per share rose to ₹299.24, reflecting improved asset retention and potential for value creation. Neogen’s financial ratios, particularly its price-to-book value (P/BV) at 5.16x, indicate a premium valuation compared to typical sector ranges, pointing to investor confidence in its growth prospects but also raising concerns about overvaluation in a volatile market.
Shareholding Pattern and Investor Confidence
Neogen Chemicals has a diversified shareholding structure, with promoters holding 51.22% of the company as of September 2025. Institutional investors, comprised of foreign institutional investors (FIIs) and domestic institutional investors (DIIs), have shown increasing interest, holding 5.15% and 25.22% respectively. This reflects growing institutional confidence in the company’s long-term growth trajectory. The public shareholding stood at 18.40%, with a total of 45,710 shareholders. Notably, the promoter holding has seen a gradual decline from 60.19% in December 2022, which may raise questions about insider confidence in the company’s future. In contrast, DIIs have increased their stake from 18.89% in December 2022, indicating strong institutional support. This mixed ownership structure suggests a blend of confidence and caution among different investor classes, as the company navigates market challenges.
Outlook, Risks, and Final Insight
Looking forward, Neogen Chemicals is positioned for growth, driven by its strategic focus on specialty chemicals and potential expansion into new markets. However, risks loom, including fluctuating raw material prices and regulatory challenges, which may impact margins. The company’s declining net profit and profitability ratios could pose challenges in sustaining investor confidence. Additionally, the rising debt levels may affect its financial flexibility, potentially constraining growth initiatives. Nevertheless, if Neogen can successfully leverage its strong reserves and maintain operational efficiency, it could capitalize on emerging opportunities in the specialty chemicals sector. The balance between growth and risk management will be crucial as the company navigates its path forward, with its ability to adapt to market dynamics determining its long-term success.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| HP Adhesives Ltd | 347 Cr. | 37.6 | 73.5/36.8 | 21.6 | 20.5 | 1.06 % | 13.6 % | 9.82 % | 2.00 |
| Haryana Leather Chemicals Ltd | 28.7 Cr. | 58.5 | 88.8/55.0 | 13.7 | 89.6 | 1.71 % | 8.02 % | 5.45 % | 10.0 |
| Hardcastle & Waud Mfg Co Ltd | 44.9 Cr. | 660 | 899/600 | 20.7 | 697 | 0.00 % | 6.31 % | 2.91 % | 10.0 |
| Grauer & Weil (India) Ltd | 3,258 Cr. | 71.8 | 111/68.2 | 21.6 | 22.0 | 0.70 % | 23.3 % | 17.6 % | 1.00 |
| DMCC Speciality Chemicals Ltd | 539 Cr. | 217 | 391/214 | 19.3 | 93.8 | 1.15 % | 14.1 % | 9.97 % | 10.0 |
| Industry Average | 12,052.84 Cr | 648.91 | 58.60 | 182.97 | 0.47% | 12.99% | 25.41% | 6.41 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148.12 | 186.25 | 203.92 | 170.12 | 168.24 | 164.47 | 210.30 | 176.34 | 193.14 | 200.41 | 203.75 | 184.58 | 206.68 |
| Expenses | 123.87 | 156.11 | 171.33 | 140.67 | 142.00 | 142.55 | 172.31 | 144.52 | 156.65 | 162.76 | 162.58 | 149.90 | 171.73 |
| Operating Profit | 24.25 | 30.14 | 32.59 | 29.45 | 26.24 | 21.92 | 37.99 | 31.82 | 36.49 | 37.65 | 41.17 | 34.68 | 34.95 |
| OPM % | 16.37% | 16.18% | 15.98% | 17.31% | 15.60% | 13.33% | 18.06% | 18.04% | 18.89% | 18.79% | 20.21% | 18.79% | 16.91% |
| Other Income | 0.50 | 1.40 | 1.77 | 1.84 | 1.87 | 1.50 | 2.82 | 2.81 | 2.24 | 2.05 | -10.91 | 3.31 | 4.37 |
| Interest | 6.86 | 6.66 | 9.34 | 10.61 | 10.75 | 10.52 | 9.64 | 9.51 | 12.30 | 13.07 | 16.50 | 14.03 | 20.60 |
| Depreciation | 3.88 | 4.14 | 4.29 | 4.92 | 4.93 | 5.74 | 5.81 | 6.39 | 6.61 | 6.58 | 6.01 | 4.88 | 6.39 |
| Profit before tax | 14.01 | 20.74 | 20.73 | 15.76 | 12.43 | 7.16 | 25.36 | 18.73 | 19.82 | 20.05 | 7.75 | 19.08 | 12.33 |
| Tax % | 29.41% | 29.07% | 30.87% | 27.54% | 26.47% | 68.58% | 24.05% | 25.57% | 25.03% | 28.13% | 33.03% | 25.42% | 24.49% |
| Net Profit | 9.89 | 14.71 | 14.33 | 11.42 | 9.14 | 2.25 | 19.26 | 13.94 | 14.86 | 14.41 | 5.19 | 14.23 | 9.31 |
| EPS in Rs | 3.97 | 5.90 | 5.75 | 4.58 | 3.66 | 0.85 | 7.30 | 5.28 | 5.63 | 5.46 | 1.97 | 5.39 | 3.53 |
Last Updated: December 29, 2025, 8:07 pm
Below is a detailed analysis of the quarterly data for Neogen Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 206.68 Cr.. The value appears strong and on an upward trend. It has increased from 184.58 Cr. (Jun 2025) to 206.68 Cr., marking an increase of 22.10 Cr..
- For Expenses, as of Sep 2025, the value is 171.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 149.90 Cr. (Jun 2025) to 171.73 Cr., marking an increase of 21.83 Cr..
- For Operating Profit, as of Sep 2025, the value is 34.95 Cr.. The value appears strong and on an upward trend. It has increased from 34.68 Cr. (Jun 2025) to 34.95 Cr., marking an increase of 0.27 Cr..
- For OPM %, as of Sep 2025, the value is 16.91%. The value appears to be declining and may need further review. It has decreased from 18.79% (Jun 2025) to 16.91%, marking a decrease of 1.88%.
- For Other Income, as of Sep 2025, the value is 4.37 Cr.. The value appears strong and on an upward trend. It has increased from 3.31 Cr. (Jun 2025) to 4.37 Cr., marking an increase of 1.06 Cr..
- For Interest, as of Sep 2025, the value is 20.60 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14.03 Cr. (Jun 2025) to 20.60 Cr., marking an increase of 6.57 Cr..
- For Depreciation, as of Sep 2025, the value is 6.39 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.88 Cr. (Jun 2025) to 6.39 Cr., marking an increase of 1.51 Cr..
- For Profit before tax, as of Sep 2025, the value is 12.33 Cr.. The value appears to be declining and may need further review. It has decreased from 19.08 Cr. (Jun 2025) to 12.33 Cr., marking a decrease of 6.75 Cr..
- For Tax %, as of Sep 2025, the value is 24.49%. The value appears to be improving (decreasing) as expected. It has decreased from 25.42% (Jun 2025) to 24.49%, marking a decrease of 0.93%.
- For Net Profit, as of Sep 2025, the value is 9.31 Cr.. The value appears to be declining and may need further review. It has decreased from 14.23 Cr. (Jun 2025) to 9.31 Cr., marking a decrease of 4.92 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.53. The value appears to be declining and may need further review. It has decreased from 5.39 (Jun 2025) to 3.53, marking a decrease of 1.86.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:54 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 74 | 84 | 100 | 110 | 161 | 239 | 306 | 336 | 487 | 686 | 701 | 774 | 795 |
| Expenses | 62 | 71 | 86 | 90 | 132 | 196 | 248 | 272 | 401 | 575 | 585 | 627 | 647 |
| Operating Profit | 11 | 13 | 14 | 20 | 29 | 43 | 58 | 64 | 87 | 112 | 116 | 147 | 148 |
| OPM % | 16% | 15% | 14% | 18% | 18% | 18% | 19% | 19% | 18% | 16% | 17% | 19% | 19% |
| Other Income | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 5 | 8 | -4 | -1 |
| Interest | 5 | 5 | 5 | 8 | 10 | 12 | 12 | 14 | 19 | 29 | 42 | 51 | 64 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 3 | 5 | 7 | 12 | 16 | 23 | 26 | 24 |
| Profit before tax | 6 | 8 | 8 | 12 | 18 | 29 | 41 | 44 | 57 | 71 | 59 | 66 | 59 |
| Tax % | 41% | 37% | 39% | 33% | 39% | 28% | 30% | 29% | 22% | 30% | 31% | 27% | |
| Net Profit | 4 | 5 | 5 | 8 | 11 | 21 | 29 | 31 | 45 | 50 | 41 | 48 | 43 |
| EPS in Rs | 8.09 | 11.31 | 2.59 | 3.88 | 5.34 | 10.48 | 12.33 | 13.47 | 17.93 | 20.07 | 15.59 | 18.35 | 16.35 |
| Dividend Payout % | 25% | 18% | 77% | 26% | 19% | 14% | 16% | 17% | 15% | 15% | 13% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 25.00% | 0.00% | 60.00% | 37.50% | 90.91% | 38.10% | 6.90% | 45.16% | 11.11% | -18.00% | 17.07% |
| Change in YoY Net Profit Growth (%) | 0.00% | -25.00% | 60.00% | -22.50% | 53.41% | -52.81% | -31.20% | 38.26% | -34.05% | -29.11% | 35.07% |
Neogen Chemicals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 20% |
| 3 Years: | 17% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 15% |
| 3 Years: | 9% |
| TTM: | 23% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | -1% |
| 1 Year: | -1% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 8% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: December 4, 2025, 1:43 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 20 | 20 | 20 | 20 | 23 | 23 | 25 | 25 | 26 | 26 | 26 |
| Reserves | 15 | 19 | 8 | 22 | 31 | 50 | 133 | 160 | 414 | 458 | 740 | 782 | 803 |
| Borrowings | 25 | 24 | 26 | 69 | 82 | 120 | 137 | 222 | 229 | 370 | 409 | 474 | 776 |
| Other Liabilities | 18 | 21 | 27 | 41 | 48 | 56 | 61 | 87 | 131 | 202 | 230 | 338 | 344 |
| Total Liabilities | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
| Fixed Assets | 14 | 13 | 17 | 56 | 67 | 83 | 111 | 127 | 285 | 347 | 361 | 228 | 251 |
| CWIP | 0 | 0 | 1 | 1 | 1 | 0 | 3 | 115 | 11 | 36 | 56 | 28 | 54 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 81 | 77 | 5 | 193 | 400 |
| Other Assets | 49 | 55 | 62 | 94 | 112 | 163 | 242 | 250 | 423 | 594 | 983 | 1,173 | 1,244 |
| Total Assets | 63 | 69 | 80 | 152 | 181 | 247 | 355 | 492 | 800 | 1,054 | 1,405 | 1,621 | 1,949 |
Below is a detailed analysis of the balance sheet data for Neogen Chemicals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 26.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 26.00 Cr..
- For Reserves, as of Sep 2025, the value is 803.00 Cr.. The value appears strong and on an upward trend. It has increased from 782.00 Cr. (Mar 2025) to 803.00 Cr., marking an increase of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 776.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 474.00 Cr. (Mar 2025) to 776.00 Cr., marking an increase of 302.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 344.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 338.00 Cr. (Mar 2025) to 344.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,949.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 251.00 Cr.. The value appears strong and on an upward trend. It has increased from 228.00 Cr. (Mar 2025) to 251.00 Cr., marking an increase of 23.00 Cr..
- For CWIP, as of Sep 2025, the value is 54.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2025) to 54.00 Cr., marking an increase of 26.00 Cr..
- For Investments, as of Sep 2025, the value is 400.00 Cr.. The value appears strong and on an upward trend. It has increased from 193.00 Cr. (Mar 2025) to 400.00 Cr., marking an increase of 207.00 Cr..
- For Other Assets, as of Sep 2025, the value is 1,244.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,173.00 Cr. (Mar 2025) to 1,244.00 Cr., marking an increase of 71.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,949.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,621.00 Cr. (Mar 2025) to 1,949.00 Cr., marking an increase of 328.00 Cr..
Notably, the Reserves (803.00 Cr.) exceed the Borrowings (776.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -14.00 | -11.00 | -12.00 | -49.00 | -53.00 | -77.00 | -79.00 | -158.00 | -142.00 | -258.00 | -293.00 | -327.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 78 | 58 | 107 | 94 | 93 | 90 | 85 | 82 | 94 | 147 | 94 |
| Inventory Days | 173 | 178 | 190 | 228 | 192 | 188 | 257 | 211 | 258 | 275 | 353 | 265 |
| Days Payable | 117 | 120 | 130 | 177 | 141 | 111 | 71 | 122 | 131 | 147 | 134 | 220 |
| Cash Conversion Cycle | 138 | 136 | 117 | 158 | 145 | 169 | 276 | 174 | 209 | 223 | 366 | 138 |
| Working Capital Days | 140 | 140 | 126 | 67 | 49 | 63 | 96 | 67 | 111 | 80 | 190 | 169 |
| ROCE % | 26% | 27% | 26% | 23% | 23% | 26% | 22% | 17% | 14% | 13% | 10% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 1,248,272 | 0.28 | 140.47 | 808,141 | 2025-12-07 15:45:16 | 54.46% |
| Axis Small Cap Fund | 1,217,809 | 0.51 | 137.04 | 1,217,809 | 2025-04-22 17:25:25 | 0% |
| SBI Large & Midcap Fund | 935,051 | 0.28 | 105.22 | 935,051 | 2025-04-22 15:56:55 | 0% |
| Sundaram Small Cap Fund | 271,539 | 0.89 | 30.56 | 243,156 | 2025-12-15 00:52:01 | 11.67% |
| Aditya Birla Sun Life Small Cap Fund | 237,614 | 0.53 | 26.74 | 311,723 | 2025-12-15 00:52:01 | -23.77% |
| Invesco India Smallcap Fund | 222,523 | 0.28 | 25.04 | N/A | N/A | N/A |
| Axis Flexi Cap Fund | 212,801 | 0.18 | 23.95 | 212,801 | 2025-04-22 15:56:55 | 0% |
| SBI Equity Savings Fund | 212,313 | 0.4 | 23.89 | 212,711 | 2025-12-15 00:52:01 | -0.19% |
| SBI Comma Fund | 152,080 | 2.06 | 17.11 | N/A | N/A | N/A |
| Axis Innovation Fund | 118,806 | 1.12 | 13.37 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Diluted EPS (Rs.) | 13.20 | 13.96 | 20.03 | 18.70 | 13.45 |
| Cash EPS (Rs.) | 23.66 | 22.11 | 26.49 | 22.58 | 16.38 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 299.24 | 288.21 | 193.47 | 176.12 | 78.43 |
| Revenue From Operations / Share (Rs.) | 294.75 | 261.82 | 275.13 | 195.37 | 144.17 |
| PBDIT / Share (Rs.) | 53.20 | 44.55 | 46.54 | 35.22 | 27.81 |
| PBIT / Share (Rs.) | 42.66 | 35.88 | 40.04 | 30.53 | 24.85 |
| PBT / Share (Rs.) | 18.94 | 19.93 | 28.44 | 22.88 | 18.95 |
| Net Profit / Share (Rs.) | 13.13 | 13.45 | 20.00 | 17.89 | 13.43 |
| NP After MI And SOA / Share (Rs.) | 13.20 | 13.51 | 20.04 | 17.89 | 13.43 |
| PBDIT Margin (%) | 18.04 | 17.01 | 16.91 | 18.02 | 19.28 |
| PBIT Margin (%) | 14.47 | 13.70 | 14.55 | 15.62 | 17.23 |
| PBT Margin (%) | 6.42 | 7.61 | 10.33 | 11.71 | 13.14 |
| Net Profit Margin (%) | 4.45 | 5.13 | 7.26 | 9.15 | 9.31 |
| NP After MI And SOA Margin (%) | 4.47 | 5.16 | 7.28 | 9.15 | 9.31 |
| Return on Networth / Equity (%) | 4.41 | 4.68 | 10.35 | 10.16 | 17.11 |
| Return on Capital Employeed (%) | 11.09 | 10.12 | 15.50 | 13.10 | 18.23 |
| Return On Assets (%) | 1.99 | 2.43 | 4.74 | 5.58 | 6.36 |
| Long Term Debt / Equity (X) | 0.21 | 0.16 | 0.26 | 0.27 | 0.63 |
| Total Debt / Equity (X) | 0.71 | 0.51 | 0.75 | 0.45 | 1.10 |
| Asset Turnover Ratio (%) | 0.48 | 0.54 | 0.74 | 0.75 | 0.79 |
| Current Ratio (X) | 1.36 | 1.49 | 1.60 | 2.26 | 1.38 |
| Quick Ratio (X) | 0.94 | 0.76 | 0.88 | 1.37 | 0.72 |
| Inventory Turnover Ratio (X) | 2.25 | 1.41 | 1.99 | 2.23 | 1.48 |
| Dividend Payout Ratio (NP) (%) | 15.15 | 20.98 | 13.72 | 11.76 | 14.89 |
| Dividend Payout Ratio (CP) (%) | 8.43 | 12.78 | 10.36 | 9.32 | 12.20 |
| Earning Retention Ratio (%) | 84.85 | 79.02 | 86.28 | 88.24 | 85.11 |
| Cash Earning Retention Ratio (%) | 91.57 | 87.22 | 89.64 | 90.68 | 87.80 |
| Interest Coverage Ratio (X) | 2.89 | 2.79 | 4.01 | 4.60 | 4.71 |
| Interest Coverage Ratio (Post Tax) (X) | 2.00 | 1.84 | 2.72 | 3.34 | 3.28 |
| Enterprise Value (Cr.) | 4637.05 | 3527.65 | 3541.31 | 4504.16 | 2217.48 |
| EV / Net Operating Revenue (X) | 5.96 | 5.11 | 5.16 | 9.24 | 6.59 |
| EV / EBITDA (X) | 33.04 | 30.02 | 30.51 | 51.28 | 34.18 |
| MarketCap / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 5.99 |
| Retention Ratios (%) | 84.84 | 79.01 | 86.27 | 88.23 | 85.10 |
| Price / BV (X) | 5.16 | 4.14 | 6.63 | 9.91 | 11.02 |
| Price / Net Operating Revenue (X) | 5.24 | 4.56 | 4.66 | 8.93 | 6.00 |
| EarningsYield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
After reviewing the key financial ratios for Neogen Chemicals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.96 (Mar 24) to 13.20, marking a decrease of 0.76.
- For Cash EPS (Rs.), as of Mar 25, the value is 23.66. This value is within the healthy range. It has increased from 22.11 (Mar 24) to 23.66, marking an increase of 1.55.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 299.24. It has increased from 288.21 (Mar 24) to 299.24, marking an increase of 11.03.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 294.75. It has increased from 261.82 (Mar 24) to 294.75, marking an increase of 32.93.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 53.20. This value is within the healthy range. It has increased from 44.55 (Mar 24) to 53.20, marking an increase of 8.65.
- For PBIT / Share (Rs.), as of Mar 25, the value is 42.66. This value is within the healthy range. It has increased from 35.88 (Mar 24) to 42.66, marking an increase of 6.78.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.94. This value is within the healthy range. It has decreased from 19.93 (Mar 24) to 18.94, marking a decrease of 0.99.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 13.45 (Mar 24) to 13.13, marking a decrease of 0.32.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.20. This value is within the healthy range. It has decreased from 13.51 (Mar 24) to 13.20, marking a decrease of 0.31.
- For PBDIT Margin (%), as of Mar 25, the value is 18.04. This value is within the healthy range. It has increased from 17.01 (Mar 24) to 18.04, marking an increase of 1.03.
- For PBIT Margin (%), as of Mar 25, the value is 14.47. This value is within the healthy range. It has increased from 13.70 (Mar 24) to 14.47, marking an increase of 0.77.
- For PBT Margin (%), as of Mar 25, the value is 6.42. This value is below the healthy minimum of 10. It has decreased from 7.61 (Mar 24) to 6.42, marking a decrease of 1.19.
- For Net Profit Margin (%), as of Mar 25, the value is 4.45. This value is below the healthy minimum of 5. It has decreased from 5.13 (Mar 24) to 4.45, marking a decrease of 0.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.47. This value is below the healthy minimum of 8. It has decreased from 5.16 (Mar 24) to 4.47, marking a decrease of 0.69.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.41. This value is below the healthy minimum of 15. It has decreased from 4.68 (Mar 24) to 4.41, marking a decrease of 0.27.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.12 (Mar 24) to 11.09, marking an increase of 0.97.
- For Return On Assets (%), as of Mar 25, the value is 1.99. This value is below the healthy minimum of 5. It has decreased from 2.43 (Mar 24) to 1.99, marking a decrease of 0.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.21, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.71. This value is within the healthy range. It has increased from 0.51 (Mar 24) to 0.71, marking an increase of 0.20.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.48. It has decreased from 0.54 (Mar 24) to 0.48, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.36. This value is below the healthy minimum of 1.5. It has decreased from 1.49 (Mar 24) to 1.36, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 25, the value is 0.94. This value is below the healthy minimum of 1. It has increased from 0.76 (Mar 24) to 0.94, marking an increase of 0.18.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 4. It has increased from 1.41 (Mar 24) to 2.25, marking an increase of 0.84.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 15.15. This value is below the healthy minimum of 20. It has decreased from 20.98 (Mar 24) to 15.15, marking a decrease of 5.83.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 8.43. This value is below the healthy minimum of 20. It has decreased from 12.78 (Mar 24) to 8.43, marking a decrease of 4.35.
- For Earning Retention Ratio (%), as of Mar 25, the value is 84.85. This value exceeds the healthy maximum of 70. It has increased from 79.02 (Mar 24) to 84.85, marking an increase of 5.83.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 91.57. This value exceeds the healthy maximum of 70. It has increased from 87.22 (Mar 24) to 91.57, marking an increase of 4.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.89. This value is below the healthy minimum of 3. It has increased from 2.79 (Mar 24) to 2.89, marking an increase of 0.10.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 2.00. This value is below the healthy minimum of 3. It has increased from 1.84 (Mar 24) to 2.00, marking an increase of 0.16.
- For Enterprise Value (Cr.), as of Mar 25, the value is 4,637.05. It has increased from 3,527.65 (Mar 24) to 4,637.05, marking an increase of 1,109.40.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.96. This value exceeds the healthy maximum of 3. It has increased from 5.11 (Mar 24) to 5.96, marking an increase of 0.85.
- For EV / EBITDA (X), as of Mar 25, the value is 33.04. This value exceeds the healthy maximum of 15. It has increased from 30.02 (Mar 24) to 33.04, marking an increase of 3.02.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For Retention Ratios (%), as of Mar 25, the value is 84.84. This value exceeds the healthy maximum of 70. It has increased from 79.01 (Mar 24) to 84.84, marking an increase of 5.83.
- For Price / BV (X), as of Mar 25, the value is 5.16. This value exceeds the healthy maximum of 3. It has increased from 4.14 (Mar 24) to 5.16, marking an increase of 1.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.24. This value exceeds the healthy maximum of 3. It has increased from 4.56 (Mar 24) to 5.24, marking an increase of 0.68.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neogen Chemicals Ltd:
- Net Profit Margin: 4.45%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.09% (Industry Average ROCE: 12.99%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.41% (Industry Average ROE: 25.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 2
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.94
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 66.7 (Industry average Stock P/E: 58.6)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 4.45%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Speciality - Others | No. 1002, 10th Floor, Dev Corpora Bldg, Thane Maharashtra 400601 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Haridas Kanani | Chairman & Managing Director |
| Dr. Harin Kanani | Managing Director |
| Mr. Shyamsunder Upadhyay | Whole Time Director |
| Mr. Anurag Surana | Non Exe.Non Ind.Director |
| Mr. Rajeshkumar Shah | Independent Director |
| Mr. Manojkumar Pati | Independent Director |
| Prof. Ranjan Kumar Malik | Independent Director |
| Mrs. Avi Sabavala | Independent Director |
FAQ
What is the intrinsic value of Neogen Chemicals Ltd?
Neogen Chemicals Ltd's intrinsic value (as of 21 January 2026) is ₹1211.60 which is 2.99% lower the current market price of ₹1,249.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹3,295 Cr. market cap, FY2025-2026 high/low of ₹2,191/967, reserves of ₹803 Cr, and liabilities of ₹1,949 Cr.
What is the Market Cap of Neogen Chemicals Ltd?
The Market Cap of Neogen Chemicals Ltd is 3,295 Cr..
What is the current Stock Price of Neogen Chemicals Ltd as on 21 January 2026?
The current stock price of Neogen Chemicals Ltd as on 21 January 2026 is ₹1,249.
What is the High / Low of Neogen Chemicals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neogen Chemicals Ltd stocks is ₹2,191/967.
What is the Stock P/E of Neogen Chemicals Ltd?
The Stock P/E of Neogen Chemicals Ltd is 66.7.
What is the Book Value of Neogen Chemicals Ltd?
The Book Value of Neogen Chemicals Ltd is 314.
What is the Dividend Yield of Neogen Chemicals Ltd?
The Dividend Yield of Neogen Chemicals Ltd is 0.08 %.
What is the ROCE of Neogen Chemicals Ltd?
The ROCE of Neogen Chemicals Ltd is 10.7 %.
What is the ROE of Neogen Chemicals Ltd?
The ROE of Neogen Chemicals Ltd is 7.36 %.
What is the Face Value of Neogen Chemicals Ltd?
The Face Value of Neogen Chemicals Ltd is 10.0.